Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

BAYRY : 5.3000 (-1.12%)
JNJ : 154.77 (+0.50%)
ORIC : 8.56 (+0.71%)
PFE : 24.86 (+0.24%)
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

ORIC : 8.56 (+0.71%)
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC : 8.56 (+0.71%)
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC : 8.56 (+0.71%)
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ORIC : 8.56 (+0.71%)
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ORIC : 8.56 (+0.71%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC : 8.56 (+0.71%)
Why Shares of Oric Pharmaceuticals Jumped Monday

Private investors agreed to spend $85 million to purchase the company's stock.

ORIC : 8.56 (+0.71%)
Pre-Market Brief: Stocks Mixed As Brutal Year Nears End

March S&P 500 futures (ESH23) are trending down -0.45% this morning after three major U.S. benchmark indices ended the regular session higher, powered by a rebound in mega-cap growth stocks as U.S. unemployment...

ESH23 : 3,957.05s (-0.09%)
META : 554.40 (+0.06%)
AAPL : 228.02 (+1.34%)
SESN : 12.5760 (+7.29%)
HOTH : 0.7910 (-3.31%)
CLLS : 1.9400 (+3.74%)
ORIC : 8.56 (+0.71%)
PFE : 24.86 (+0.24%)
TGTX : 29.61 (+0.24%)
Pre-Market Brief: Stocks Mostly Lower Ahead of Key U.S. GDP Data

March S&P 500 futures (ESH23) are trending down -0.10% this morning after three major U.S. benchmark indices rallied on Wednesday, notching their biggest one-day percentage gains this month as upbeat corporate...

ESH23 : 3,957.05s (-0.09%)
NKE : 74.89 (-2.31%)
FDX : 295.21 (+0.25%)
ISO : 0.7616 (+2.78%)
MU : 97.51 (+1.21%)
LRCX : 70.57 (+0.74%)
MRTX : 58.70 (-0.17%)
ORIC : 8.56 (+0.71%)
LXRX : 0.9050 (-7.20%)

Barchart Exclusives

Is It Time to Buy This Dividend Stock With Nuclear Energy Upside?
Apart from its prowess in nuclear energy, this energy company is also deploying AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar